Exposure of CD34 + precursors to cytostatic anthraquinone- derivatives induces rapid dendritic cell differentiation: Implications for cancer immunotherapy

Cancer Immunology, Immunotherapy

Volumn 61, Issue 2, 2012, Pages 181-191

  Van De Ven, Rieneke ^a   Reurs, Anneke W ^a,b   Wijnands, Pepijn G J T B ^a,b   Van Wetering, Sandra ^b   Kruisbeek, Ada M ^b   Hooijberg, Erik ^a   Scheffer, George L ^a   Scheper, Rik J ^a,b   De Gruijl, Tanja D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DCPrime BV   (Netherlands)

Author keywords

CD34 + precursors; Cytostatic drugs; Dendritic cell; Differentiation; Immunotherapy; Mitoxantrone

Indexed keywords

CD14 ANTIGEN; CD34 ANTIGEN; DOXORUBICIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MELAN A; MITOXANTRONE; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL HOMING; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTHRACYCLINES; ANTHRAQUINONES; ANTIGENS, CD14; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL DIFFERENTIATION; CELL LINE; CHEMOKINE CCL19; CHEMOKINE CCL21; CYTOSTATIC AGENTS; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MYELOID PROGENITOR CELLS; NEOPLASMS;

EID: 84856763717     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1039-x     Document Type: Article

References (41)

1. L Apetoh F Ghiringhelli A Tesniere, et al. 2007 Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat Med 13 1050 1059 17704786 10.1038/nm1622 1:CAS:528: DC%2BD2sXhtVSgtr3E (Pubitemid 47517504)
2. J Banchereau F Briere C Caux, et al. 2000 Immunobiology of dendritic cells Annu Rev Immunol 18 767 811 10837075 10.1146/annurev.immunol.18.1.767 1:CAS:528:DC%2BD3cXjs1GmtrY%3D (Pubitemid 30365397)
3. A Bettaieb I Plo V Mansat-de Mas, et al. 1999 Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation and apoptosis Mol Pharmacol 55 118 125 9882705 1:CAS:528:DyaK1MXjs1Kmtw%3D%3D (Pubitemid 29042529)
4. HJ Bontkes TD de Gruijl GJ Schuurhuis, et al. 2002 Expansion of dendritic cell precursors from human CD34(+) progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome J Leukoc Biol 72 321 329 12149423 1:CAS:528:DC%2BD38XlvFeqsLg%3D
5. F Bosch A Ferrer N Villamor, et al. 2008 Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication Clin Cancer Res 14 155 161 18172266 10.1158/1078-0432.CCR-07-1371 1:CAS:528:DC%2BD1cXoslCq (Pubitemid 351377991)
6. PJ Cejas LM Carlson D Kolonias, et al. 2005 Regulation of RelB expression during the initiation of dendritic cell differentiation Mol Cell Biol 25 7900 7916 16107733 10.1128/MCB.25.17.7900-7916.2005 1:CAS:528:DC%2BD2MXpsFKht7o%3D (Pubitemid 41170148)
7. GJ Clark S Gunningham A Troy, et al. 1999 Expression of the RelB transcription factor correlates with the activation of human dendritic cells Immunology 98 189 196 10540217 10.1046/j.1365-2567.1999.00829.x 1:CAS:528:DyaK1MXmslKiu7k%3D (Pubitemid 29487639)
8. TA Davis AA Saini PJ Blair, et al. 1998 Phorbol esters induce differentiation of human CD34+ hemopoietic progenitors to dendritic cells: evidence for protein kinase C-mediated signaling J Immunol 160 3689 3697 9558069 1:CAS:528:DyaK1cXis1ers78%3D (Pubitemid 28176069)
9. DI Gabrilovich J Corak IF Ciernik, et al. 1997 Decreased antigen presentation by dendritic cells in patients with breast cancer Clin Cancer Res 3 483 490 9815709 1:STN:280:DyaK1M%2FjsFejuw%3D%3D (Pubitemid 27158075)
10. R Kaneno GV Shurin IL Tourkova, et al. 2009 Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations J Transl Med 7 58 19591684 10.1186/1479-5876-7-58
11. S Kusmartsev DI Gabrilovich 2006 Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer Cancer Metastasis Rev 25 323 331 16983515 10.1007/s10555-006- 9002-6 1:CAS:528:DC%2BD28Xht1yktb3O (Pubitemid 44922353)
12. J Limpens J Garssen WT Germeraad, et al. 1990 Enhancing effects of locally administered cytostatic drugs on T effector cell functions in mice Int J Immunopharmacol 12 77 88 2303320 10.1016/0192-0561(90)90070-4 1:CAS:528:DyaK3cXhtFWks78%3D (Pubitemid 20034213)
13. J Limpens M Van Meijer HM Van Santen, et al. 1991 Alterations in dendritic cell phenotype and function associated with immunoenhancing effects of a subcutaneously administered cyclophosphamide derivative Immunology 73 255 263 1879874 1:CAS:528:DyaK3MXlsV2qtLY%3D
14. HJ Long III RA Nelimark KC Podratz, et al. 2006 Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) versus doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium Gynecol Oncol 100 501 505 16185755 10.1016/j.ygyno.2005.08.021 1:CAS:528:DC%2BD28XhsFKrtrY%3D (Pubitemid 43246865)
15. AJ Masterson CC Sombroek TD de Gruijl, et al. 2002 MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors Blood 100 701 703 12091369 10.1182/blood.V100.2.701 1:CAS:528:DC%2BD38XlsVWgur8%3D (Pubitemid 34761140)
16. D Messmer H Yang G Telusma, et al. 2004 High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization J Immunol 173 307 313 15210788 1:CAS:528:DC%2BD2cXltVaju7k%3D (Pubitemid 38797355)
17. AS Michallet B Coiffier 2008 Recent developments in the treatment of aggressive non-Hodgkin lymphoma Blood Rev 23 11 23 18620786 10.1016/j.blre.2008. 05.002
18. Mike S, Harrison C, Coles B et al (2006) Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev CD005247
19. A Onyenadum H Gogas P Kosmidis, et al. 2006 Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer J Chemother 18 192 198 16736889 1:CAS:528:DC%2BD28XlvVWhtLk%3D (Pubitemid 43774295)
20. F Ouaaz J Arron Y Zheng, et al. 2002 Dendritic cell development and survival require distinct NF-kappaB subunits Immunity 16 257 270 11869686 10.1016/S1074-7613(02)00272-8 1:CAS:528:DC%2BD38XitVCisrs%3D (Pubitemid 34211965)
21. B Oyan Y Koc E Ozdemir, et al. 2006 High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma Leuk Lymphoma 47 1545 1552 16966265 10.1080/10428190600570958 1:CAS:528:DC%2BD28XhtFKjtr3P (Pubitemid 44364019)
22. AK Palucka H Ueno JW Fay, et al. 2007 Taming cancer by inducing immunity via dendritic cells Immunol Rev 220 129 150 17979844 10.1111/j.1600-065X.2007. 00575.x 1:CAS:528:DC%2BD2sXhsVKgtrrK (Pubitemid 350045575)
23. SS Pendse S Behjati T Schatton, et al. 2006 P-glycoprotein functions as a differentiation switch in antigen presenting cell maturation Am J Transplant 6 2884 2893 17083370 10.1111/j.1600-6143.2006.01561.x 1:CAS:528: DC%2BD2sXhtVGitA%3D%3D
24. J Posada P Vichi TR Tritton 1989 Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells Cancer Res 49 6634 6639 2819714 1:CAS:528:DyaK3cXhs1Shsg%3D%3D (Pubitemid 20008800)
25. E Rubin S Kharbanda H Gunji, et al. 1992 cis-Diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway Cancer Res 52 878 882 1737349 1:CAS:528:DyaK38XhsVensLk%3D
26. SJ Santegoets HJ Bontkes AG Stam, et al. 2008 Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model J Immunol 180 4540 4549 18354176 1:CAS:528:DC%2BD1cXjsVKqsL4%3D
27. SJ Santegoets AJ Masterson PC van der Sluis, et al. 2006 A CD34+ human cell line model of myeloid dendritic cell differentiation: evidence for a CD14+ CD11b+ Langerhans cell precursor J Leukoc Biol 80 1337 1344 16959899 10.1189/jlb.0206111 1:CAS:528:DC%2BD28XhtlSisLnE (Pubitemid 44904972)
28. SJ Santegoets MW Schreurs AJ Masterson, et al. 2006 In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line Cancer Immunol Immunother 55 1480 1490 16468034 10.1007/s00262-006-0142-x (Pubitemid 44327836)
29. SJ Santegoets AJ van den Eertwegh AA van de Loosdrecht, et al. 2008 Human dendritic cell line models for DC differentiation and clinical DC vaccination studies J Leukoc Biol 84 1364 1373 18664532 10.1189/jlb.0208092 1:CAS:528:DC%2BD1cXhsVKhsrbM (Pubitemid 352774471)
30. RJ Scheper J Limpens BT Tan, et al. 1987 Immunotherapeutic effects of local chemotherapy with an active metabolite of cyclophosphamide Methods Find Exp Clin Pharmacol 9 611 615 3325717 1:CAS:528:DyaL1cXmvVWiuw%3D%3D (Pubitemid 18031281)
31. LJ Scott DP Figgitt 2004 Mitoxantrone: a review of its use in multiple sclerosis CNS Drugs 18 379 396 15089110 10.2165/00023210-200418060-00010 1:CAS:528:DC%2BD2cXkslOmt78%3D (Pubitemid 38621687)
32. GV Shurin IL Tourkova R Kaneno, et al. 2009 Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism J Immunol 183 137 144 19535620 10.4049/jimmunol.0900734 1:CAS:528:DC%2BD1MXnsVOrtb8%3D
33. DC St Louis JB Woodcock G Franzoso, et al. 1999 Evidence for distinct intracellular signaling pathways in CD34+ progenitor to dendritic cell differentiation from a human cell line model J Immunol 162 3237 3248 10092775 1:CAS:528:DyaK1MXhvV2rtLg%3D (Pubitemid 29313570)
34. GD Stockman LR Heim MA South, et al. 1973 Differential effects of cyclophosphamide on the B and T cell compartments of adult mice J Immunol 110 277 282 4539834 1:CAS:528:DyaE3sXltlSqsQ%3D%3D
35. R van de Ven MC de Jong AW Reurs, et al. 2006 Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation J Immunol 176 5191 5198 16621983
36. SF van Helden FN van Leeuwen CG Figdor 2008 Human and murine model cell lines for dendritic cell biology evaluated Immunol Lett 117 191 197 18384885 10.1016/j.imlet.2008.02.003
37. A van Loevezijn JD Allen AH Schinkel, et al. 2001 Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines Bioorg Med Chem Lett 11 29 32 11140726 10.1016/S0960-894X(00)00588-6 (Pubitemid 32006117)
38. van de Ven R, Lindenberg JJ, Reurs AW et al (2011) Preferential Langerhans cell differentiation from CD34(+) precursors upon introduction of ABCG2 (BCRP). Immunol Cell Biol (in press)
39. DA Yardley HA Burris III CP Farley, et al. 2008 A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer Clin Breast Cancer 8 242 248 18650154 10.3816/CBC.2008.n.027 1:CAS:528:DC%2BD1cXovFCiu7k%3D (Pubitemid 351962145)
40. H Yssel JE De Vries M Koken, et al. 1984 Serum-free medium for generation and propagation of functional human cytotoxic and helper T cell clones J Immunol Methods 72 219 227 6086760 10.1016/0022-1759(84)90450-2 1:CAS:528:DyaL2cXltVylsL4%3D (Pubitemid 14092011)
41. B Yu S Kusmartsev F Cheng, et al. 2003 Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer Clin Cancer Res 9 285 294 12538481 1:CAS:528:DC%2BD3sXnt1Orsw%3D%3D (Pubitemid 36109745)